Julius Clinical appoints Bassem Saleh as CEO
Charlie Blackie-Kelly | October 16, 2025 | Appointment | | Julius Clinical, cardiometabolic diseases, central nervous system
Julius Clinical, a Netherlands-based clinical research organisation (CRO), has appointed Bassem Saleh as its new chief executive officer (CEO).
Saleh said: “As treatments become increasingly personalised, the industry is in greater need of mid-sized, therapeutically focused global CROs. Julius Clinical’s operating model…positions us well to lead in this space.”
The CRO conducts phase 1-3 and real-world evidence (RWE) trials across Europe and North America, with a particular focus on central nervous system (CNS), cardiometabolic and rare disease studies.
Saleh brings leadership experience from both large and mid-sized CROs, most recently serving as CEO of TFS HealthScience. His background includes overseeing international growth, mergers and acquisitions, and the development of specialised therapeutic business areas in CNS, ophthalmology, dermatology and oncology. At Julius Clinical, he will be responsible for driving global expansion and strengthening the organisation’s biotech and pharma client base.
Daniel Spasic, chairman of the board at Julius Clinical commented: “[Saleh’s] extensive experience leading and scaling global clinical CROs, combined with his deep understanding of industry dynamics and the needs of our biotech and pharma partners, positions him to contribute meaningfully to Julius Clinical’s long-term growth.”
Outgoing CEO Martijn Wallert, who has led the company since June 2021, will transition to a new role as board advisor.
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial
Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced …
